Cargando…
Serum 25-hydroxyvitamin D concentration in childhood and risk of islet autoimmunity and type 1 diabetes: the TRIGR nested case–control ancillary study
AIMS/HYPOTHESIS: Our aim was to study the association between serum 25-hydroxyvitamin D (25OHD) concentration and islet autoimmunity and type 1 diabetes in children with an increased genetic risk of type 1 diabetes. METHODS: Serum samples for 25OHD measurements were obtained in the Trial to Reduce I...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054378/ https://www.ncbi.nlm.nih.gov/pubmed/31912198 http://dx.doi.org/10.1007/s00125-019-05077-4 |
_version_ | 1783503184910614528 |
---|---|
author | Miettinen, Maija E. Niinistö, Sari Erlund, Iris Cuthbertson, David Nucci, Anita M. Honkanen, Jarno Vaarala, Outi Hyöty, Heikki Krischer, Jeffrey P. Knip, Mikael Virtanen, Suvi M. |
author_facet | Miettinen, Maija E. Niinistö, Sari Erlund, Iris Cuthbertson, David Nucci, Anita M. Honkanen, Jarno Vaarala, Outi Hyöty, Heikki Krischer, Jeffrey P. Knip, Mikael Virtanen, Suvi M. |
author_sort | Miettinen, Maija E. |
collection | PubMed |
description | AIMS/HYPOTHESIS: Our aim was to study the association between serum 25-hydroxyvitamin D (25OHD) concentration and islet autoimmunity and type 1 diabetes in children with an increased genetic risk of type 1 diabetes. METHODS: Serum samples for 25OHD measurements were obtained in the Trial to Reduce IDDM in the Genetically at Risk (TRIGR) ancillary study (Divia) from children in 15 countries. Case children (n = 244) were defined as having positivity for at least two out of four diabetes-associated autoantibodies measured at any one sample. For each case child, two control children were selected matched for country and date of birth (±1 year) (n = 488). Of the case children, 144 developed type 1 diabetes. Serum 25OHD was measured repeatedly in infancy and childhood and was compared according to age at the first seroconversion (at 6, 12 and 18 months prior to and at seroconversion) and calendar age (0, 6, 12 and 18 months). RESULTS: In children with islet autoimmunity, mean serum 25OHD concentration was lower 18 months prior to the age of first seroconversion of the case children compared with the control children (57.7 vs 64.8 nmol/l, p = 0.007). In children with type 1 diabetes (n = 144), mean serum 25OHD concentration was lower 18 months prior to the age of the first seroconversion (58.0 vs 65.0 nmol/l, p = 0.018) and at the calendar age of 12 months (70.1 vs 75.9 nmol/l, p = 0.031) than in their control counterparts. Analyses were adjusted for month of sample collection, human leucocyte antigen genotype, maternal type 1 diabetes and sex. CONCLUSIONS/INTERPRETATION: The results suggest that early postnatal vitamin D may confer protection against the development of type 1 diabetes. TRIAL REGISTRATION: ClinicalTrials.gov NCT00179777 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00125-019-05077-4) contains contains peer-reviewed but unedited supplementary material, which is available to authorised users. |
format | Online Article Text |
id | pubmed-7054378 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-70543782020-03-16 Serum 25-hydroxyvitamin D concentration in childhood and risk of islet autoimmunity and type 1 diabetes: the TRIGR nested case–control ancillary study Miettinen, Maija E. Niinistö, Sari Erlund, Iris Cuthbertson, David Nucci, Anita M. Honkanen, Jarno Vaarala, Outi Hyöty, Heikki Krischer, Jeffrey P. Knip, Mikael Virtanen, Suvi M. Diabetologia Article AIMS/HYPOTHESIS: Our aim was to study the association between serum 25-hydroxyvitamin D (25OHD) concentration and islet autoimmunity and type 1 diabetes in children with an increased genetic risk of type 1 diabetes. METHODS: Serum samples for 25OHD measurements were obtained in the Trial to Reduce IDDM in the Genetically at Risk (TRIGR) ancillary study (Divia) from children in 15 countries. Case children (n = 244) were defined as having positivity for at least two out of four diabetes-associated autoantibodies measured at any one sample. For each case child, two control children were selected matched for country and date of birth (±1 year) (n = 488). Of the case children, 144 developed type 1 diabetes. Serum 25OHD was measured repeatedly in infancy and childhood and was compared according to age at the first seroconversion (at 6, 12 and 18 months prior to and at seroconversion) and calendar age (0, 6, 12 and 18 months). RESULTS: In children with islet autoimmunity, mean serum 25OHD concentration was lower 18 months prior to the age of first seroconversion of the case children compared with the control children (57.7 vs 64.8 nmol/l, p = 0.007). In children with type 1 diabetes (n = 144), mean serum 25OHD concentration was lower 18 months prior to the age of the first seroconversion (58.0 vs 65.0 nmol/l, p = 0.018) and at the calendar age of 12 months (70.1 vs 75.9 nmol/l, p = 0.031) than in their control counterparts. Analyses were adjusted for month of sample collection, human leucocyte antigen genotype, maternal type 1 diabetes and sex. CONCLUSIONS/INTERPRETATION: The results suggest that early postnatal vitamin D may confer protection against the development of type 1 diabetes. TRIAL REGISTRATION: ClinicalTrials.gov NCT00179777 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00125-019-05077-4) contains contains peer-reviewed but unedited supplementary material, which is available to authorised users. Springer Berlin Heidelberg 2020-01-07 2020 /pmc/articles/PMC7054378/ /pubmed/31912198 http://dx.doi.org/10.1007/s00125-019-05077-4 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Miettinen, Maija E. Niinistö, Sari Erlund, Iris Cuthbertson, David Nucci, Anita M. Honkanen, Jarno Vaarala, Outi Hyöty, Heikki Krischer, Jeffrey P. Knip, Mikael Virtanen, Suvi M. Serum 25-hydroxyvitamin D concentration in childhood and risk of islet autoimmunity and type 1 diabetes: the TRIGR nested case–control ancillary study |
title | Serum 25-hydroxyvitamin D concentration in childhood and risk of islet autoimmunity and type 1 diabetes: the TRIGR nested case–control ancillary study |
title_full | Serum 25-hydroxyvitamin D concentration in childhood and risk of islet autoimmunity and type 1 diabetes: the TRIGR nested case–control ancillary study |
title_fullStr | Serum 25-hydroxyvitamin D concentration in childhood and risk of islet autoimmunity and type 1 diabetes: the TRIGR nested case–control ancillary study |
title_full_unstemmed | Serum 25-hydroxyvitamin D concentration in childhood and risk of islet autoimmunity and type 1 diabetes: the TRIGR nested case–control ancillary study |
title_short | Serum 25-hydroxyvitamin D concentration in childhood and risk of islet autoimmunity and type 1 diabetes: the TRIGR nested case–control ancillary study |
title_sort | serum 25-hydroxyvitamin d concentration in childhood and risk of islet autoimmunity and type 1 diabetes: the trigr nested case–control ancillary study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054378/ https://www.ncbi.nlm.nih.gov/pubmed/31912198 http://dx.doi.org/10.1007/s00125-019-05077-4 |
work_keys_str_mv | AT miettinenmaijae serum25hydroxyvitamindconcentrationinchildhoodandriskofisletautoimmunityandtype1diabetesthetrigrnestedcasecontrolancillarystudy AT niinistosari serum25hydroxyvitamindconcentrationinchildhoodandriskofisletautoimmunityandtype1diabetesthetrigrnestedcasecontrolancillarystudy AT erlundiris serum25hydroxyvitamindconcentrationinchildhoodandriskofisletautoimmunityandtype1diabetesthetrigrnestedcasecontrolancillarystudy AT cuthbertsondavid serum25hydroxyvitamindconcentrationinchildhoodandriskofisletautoimmunityandtype1diabetesthetrigrnestedcasecontrolancillarystudy AT nuccianitam serum25hydroxyvitamindconcentrationinchildhoodandriskofisletautoimmunityandtype1diabetesthetrigrnestedcasecontrolancillarystudy AT honkanenjarno serum25hydroxyvitamindconcentrationinchildhoodandriskofisletautoimmunityandtype1diabetesthetrigrnestedcasecontrolancillarystudy AT vaaralaouti serum25hydroxyvitamindconcentrationinchildhoodandriskofisletautoimmunityandtype1diabetesthetrigrnestedcasecontrolancillarystudy AT hyotyheikki serum25hydroxyvitamindconcentrationinchildhoodandriskofisletautoimmunityandtype1diabetesthetrigrnestedcasecontrolancillarystudy AT krischerjeffreyp serum25hydroxyvitamindconcentrationinchildhoodandriskofisletautoimmunityandtype1diabetesthetrigrnestedcasecontrolancillarystudy AT knipmikael serum25hydroxyvitamindconcentrationinchildhoodandriskofisletautoimmunityandtype1diabetesthetrigrnestedcasecontrolancillarystudy AT virtanensuvim serum25hydroxyvitamindconcentrationinchildhoodandriskofisletautoimmunityandtype1diabetesthetrigrnestedcasecontrolancillarystudy AT serum25hydroxyvitamindconcentrationinchildhoodandriskofisletautoimmunityandtype1diabetesthetrigrnestedcasecontrolancillarystudy |